TABLE 2.
Bone remodeling indices on cancellous bone surfaces in OVX huRANKL mice treated with Aln, DMAb, Aln plus PTH, or DMAb plus PTH
In parenthesis are the number of mice per group.
| Sham (6) | OVX |
||||||
|---|---|---|---|---|---|---|---|
| No PTH |
PTH |
||||||
| Veh (6) | Aln (8) | DMAb (6) | Veh (3) | Aln (5) | DMAb (5) | ||
| Single-labeled bone surface/BS (%) | 0.928 ± 0.074 | 1.580 ± 0.119a | 1.150 ± 0.111b | n.d. | 0.653 ± 0.080d | 0.810 ± 0.118d,f | 0.497 ± 0.149d,g |
| Double-labeled bone surface/BS (%) | 0.652 ± 0.088 | 0.751 ± 0.297 | 0.069 ± 0.012b | n.d. | 1.117 ± 0.117d | 0.591 ± 30.050d,f | 0.338 ± 0.206d,f |
| MS/BS (%) | 22.78 ± 2.06 | 22.84 ± 2.82 | 12.16 ± 0.9b | n.d. | 31.18 ± 1.02d | 26.24 ± 0.83d | 11.51 ± 4.57d,f,g |
| MAR (μm/day) | 1.71 ± 0.17 | 1.50 ± 0.07 | 1.30 ± 0.17 | n.d. | 1.99 ± 0.03 | 1.50 ± 0.24 | 1.31 ± 0.20d,f |
| BFR/BS (μm3/μm2/day) | 0.38 ± 0.05 | 0.35 ± 0.06 | 0.16 ± 0.03b | n.d. | 0.62 ± 0.01d | 0.39 ± 0.06d,f | 0.17 ± 0.08d,f,g |
| OcS/BS (%) | 8.87 ± 1.28 | 10.29 ± 0.92 | 16.11 ± 1.58b | 0.78 ± 0.10b,c | 8.37 ± 0.29 | 13.056 ± 2.05f | 5.12 ± 1.29d,g |
| OcN (/mm) | 50.7 ± 6.2 | 29.2 ± 6.7 | 134.4 ± 13.2b | 8.1 ± 1.3c | 35.0 ± 3.1 | 91.4 ± 17.8d,f | 39.8 ± 9.7d,g |
a p < 0.05 compared with sham.
b p < 0.05 compared with OVX Veh.
c p < 0.05 compared with OVX Aln.
d p < 0.05 compared with non-PTH in the same pretreatment group.
f p < 0.05 compared with OVX Veh-PTH.
g p < 0.05 compared with OVX-Veh-Aln.
n.d., not detectable.